Medtronic is one annual increase away from becoming a Dividend King after raising its payout for the 49th consecutive year in June. The medical device maker’s stock has fallen 33% over five years and trades at $87, or 15 times forward earnings, with a 3.4% forward yield. Wall Street analysts hold a median price target of $100 per share and none rate the stock a sell. In fiscal 2026, revenue rose 8.4% to $36.4 billion, the strongest top-line growth in a decade, and free cash flow reached $5.43 billion, comfortably covering $3.64 billion in dividends. Analysts project revenue and earnings per share to grow at compound annual rates of 5% and 13%, respectively, through fiscal 2029, supported by new products such as the Affera Pulsed Field Ablation system, the Symplicity Spyral renal denervation system, and the Hugo robotic-assisted surgery platform.
Medtronic PLCMedtronic is the subject; strong revenue growth, free cash flow covering dividends, and Wall Street upside with no sell ratings.
Intuitive Surgical Inc
MiniMed Group, Inc. Common Stock